Lyophilization Stabilizer Optimization for Pharmaceutical Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lyophilization methods for pharmaceutical substances face challenges in maintaining the integrity and biological activity of pharmaceuticals, achieving scalable, reproducible, and cost-efficient stabilization, especially in storing these substances at various temperatures and over extended periods.
Innovation Solution
A method involving a specific ratio of stabilizer to pharmaceutical substance, including the use of lipid nanoparticles, is employed for lyophilization. This method includes a freezing step, primary drying under reduced pressure, and secondary drying at a controlled heating rate to produce a stable lyophilized composition that maintains colloidal stability and encapsulation, suitable for storage as a liquid, frozen, or dried solid.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional lyophilization methods are used with high stabilizer to protein ratios, then protein stability is improved, but manufacturing cost and formulation complexity increase
Solution Approach 1:
The invention changes the critical parameter from stabilizer to protein ratio to mRNA to lipid ratio, and from amorphous matrix to crystalline matrix structure. By optimizing these parameters, the patent achieves stable formulations with reduced stabilizer requirements, thereby reducing formulation complexity while maintaining reliability
Solution Approach 2:
The invention uses composite lipid nanoparticle structures with specific lipid compositions and crystalline matrix formations. These composite materials provide both stability and structural integrity, allowing reduced stabilizer ratios while maintaining protein stability during lyophilization
2Reliability
If high stabilizer to protein ratios are used for stabilization, then storage stability is improved, but manufacturing cost increases
Solution Approach 1:
The invention optimizes the mRNA to lipid ratio and stabilizer to protein ratio parameters to achieve cost-effective formulations. By finding the optimal parameter range, the patent reduces the quantity of expensive stabilizers needed while maintaining storage stability, thereby reducing manufacturing cost
3Ease of operation
If conventional lyophilization cycles are used, then process simplicity is maintained, but product integrity and biological activity may be compromised
Solution Approach 1:
The invention incorporates preliminary freezing steps and pre-formulation optimization before lyophilization. By preparing the formulation in advance with optimized lipid and stabilizer ratios, the patent ensures product integrity is maintained throughout the process while keeping the actual lyophilization cycle simple and straightforward
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method ensures long-term stability and maintains product attributes during and after reconstitution, allowing for storage at ambient or subambient temperatures, thereby enhancing storage stability compared to prior art compositions.
Implementation Method 1
water present in a pharmaceutical substance is converted to ice during a freezing step
Implementation Method 2
removed from the pharmaceutical substance by direct sublimation under low-pressure conditions during a primary drying step
Implementation Method 3
Additional drying step (secondary drying) at elevated temperature is therefore required to remove residual moisture
Data Source
AI summary
This invention relates to enhanced stabilization and improved lyophilization methods of pharmaceutical substances.